SCTbio Expands into the U.S. Market
- Europe-based cell therapy CDMO SCTbio enters U.S. market by establishing its new office in Boston
- Expansion is supported by a strategic partnership with Propel BioSciences
Press Release, Prague, Czech Republic, and Boston, Massachusetts, October 7, 2024
SCTbio, a leading contract development and manufacturing organization (CDMO) specializing in cell-based therapies and viral vectors, has established a new office in Boston, Massachusetts. The new office will provide local representation to better serve U.S.-based clients, offering comprehensive services in cell and vector manufacturing and leukapheresis network solutions to support clinical trials and commercialization efforts both in the U.S. and globally.
As part of this strategic move, SCTbio has announced a strategic partnership with Propel BioSciences, a boutique consultancy specializing in global commercialization strategy and execution, with a particular focus on the cell and gene therapy market as well as the broader biotech sector. This collaboration marks a significant milestone in SCTbio’s expansion into the United States, enhancing its ability to serve clients in one of the world's most dynamic markets for cell and gene therapy innovation.
Propel Biosciences is led by Susan Nichols, an accomplished executive with 14 years' experience in the cell and gene therapy field. As well as her role as CEO of Propel Biosciences, she is also on the Board of Directors for the Alliance for Regenerative Medicine. Susan is a strategic and visionary leader who consistently delivers expertise and growth to stakeholders and clients.
“We are thrilled to announce our commitment to the U.S. market, which is a global leader in cell and gene therapy innovation,” said Ludek Sojka, CEO of SCTbio. “The demand for high-quality cell and vector manufacturing and leukapheresis materials is rapidly increasing as the field advances. Our team brings over 14 years of experience in clinical trial manufacturing, and we are eager to support U.S.-based biopharmaceutical companies in advancing their therapies from process development through to Phase III clinical trials and beyond.”
Susan Nichols added, “I am delighted to support SCTbio in expanding its footprint in the U.S. market. Having worked closely with SCTbio for many years, I have witnessed their commitment to delivering high-quality, cost-effective cell therapy manufacturing solutions. Their track record and dedication to excellence set a benchmark in the industry, and I am confident this partnership will greatly benefit U.S. companies looking for reliable and experienced manufacturing partners.”
Through this partnership, SCTbio and Propel BioSciences aim to address the critical need for global manufacturing capacity in cell therapies, viral vectors, and leukapheresis materials. Both organizations are committed to pushing the boundaries of innovation, delivering the highest quality products and services to drug developers and healthcare professionals worldwide to advance medical research and the development of personalized therapies that improve patient outcomes.
About Propel BioSciences
Propel BioSciences is a boutique consultancy specializing in commercialization strategy, planning, and execution for the cell and gene therapy market. Leveraging deep industry knowledge and experience, Propel BioSciences helps companies navigate the complexities of market entry, sales, marketing, and business development to achieve optimal market positioning, effective sales strategies, and sustainable growth in the rapidly evolving field of cell and gene therapy. For more information, please visit https://propelbiosciences.com/.
Business contact:
Pascale Charbonnel
Chief Business Officer
M: +420 720 029 922
E: [email protected]
